Biospecifics Technologies Corp. (BSTC)
| Market Cap | 650.25M |
| Revenue (ttm) | 36.59M |
| Net Income (ttm) | 17.36M |
| Shares Out | 7.34M |
| EPS (ttm) | 2.36 |
| PE Ratio | 37.51 |
| Forward PE | 17.61 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Dec 1, 2021 |
| Last Price | $88.53 |
| Previous Close | $88.53 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 88.47 |
| Day's Range | 88.44 - 88.57 |
| Day's Volume | 88,956 |
| 52-Week Range | 0.00 - 88.57 |
News
NEW YORK, Oct. 27, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection wi...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpeci...
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...
New York, New York--(Newsfile Corp. - October 21, 2020) - [DATELINE]Rowley Law PLLC is investigating potential securities law violations by BioSpecifics Technologies Corp. (NASDAQ: BSTC) and i...
Investors are fired up about Endo's planned acquisition of BioSpecifics.
New York, New York--(Newsfile Corp. - October 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased BioSpecifics Technologies C...
News that Endo International PLC (NASDAQ: ENDP) would acquire BioSpecifics Technologies Corp.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioSpecifics Technologies Corp. (NASDAQ: BSTC) to Endo International plc fo...
WILMINGTON, Del., Oct. 19, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has entered into a definitive merger agreement under which Endo Internati...
-- Endo to acquire BioSpecifics in an accretive all-cash transaction -- DUBLIN, Oct. 19, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced it has agreed to acquire all...
WILMINGTON, Del., Sept. 14, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp.
WILMINGTON, Del., Sept. 8, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp.
BioSpecifics (BSTC) delivered earnings and revenue surprises of 320.00% and 89.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of BioSpecifics Technologies (NASDAQ:BSTC) rose 2% in pre-market trading after the company reported Q2 results.
BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WILMINGTON, Del., July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp.
BioSpecifics Technologies Could Surge If The FDA Approves Its 'CCH' In XiaFlex To Treat Cellulite In The Buttocks
Cash is the lifeblood of any business, and provides vitality and strength to a company.
Is (BSTC) Outperforming Other Medical Stocks This Year?
Cash provides vitality and strength to a company. It holds the key to the company's existence, development and success, and can indeed be referred to as its lifeblood.
Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.
Is (BSTC) Outperforming Other Medical Stocks This Year?
BioSpecifics (BSTC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
As of March 30, the following companies could be undervalued by the market, as their price-earnings ratios are below 20 and their price-earnings to growth (aka PEG) ratios stand below 1.
BioSpecifics (BSTC) delivered earnings and revenue surprises of 13.33% and 6.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioSpecifics (BSTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.
In the long-run, does consistent market timing really matter to be a successful investor?
Biospecifics has recurring royalty revenue expected to grow 10%-15% annually from two Xiaflex indications.
BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.
BioSpecifics (BSTC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
About BSTC
BioSpecifics Technologies, a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement wi... [Read more...]
| Industry Biotechnology | IPO Date Nov 14, 1991 |
| Stock Exchange NASDAQ | Ticker Symbol BSTC |
Financial Performance
In 2019, BSTC's revenue was $38.19 million, an increase of 15.86% compared to the previous year's $32.96 million. Earnings were $24.47 million, an increase of 22.02%.